First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Sees Significant Drop in Short Interest

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 700 shares, a drop of 41.7% from the January 31st total of 1,200 shares. Based on an average daily volume of 2,800 shares, the short-interest ratio is presently 0.3 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Down 0.2 %

Shares of FTXH traded down $0.06 during trading on Monday, reaching $28.18. 2,226 shares of the company traded hands, compared to its average volume of 3,226. First Trust Nasdaq Pharmaceuticals ETF has a twelve month low of $25.73 and a twelve month high of $29.72. The stock has a market cap of $15.50 million, a PE ratio of 20.07 and a beta of 0.63. The stock has a 50-day simple moving average of $27.41 and a 200-day simple moving average of $28.13.

First Trust Nasdaq Pharmaceuticals ETF Increases Dividend

The business also recently declared a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Friday, December 13th were given a dividend of $0.1304 per share. The ex-dividend date was Friday, December 13th. This is a boost from First Trust Nasdaq Pharmaceuticals ETF’s previous dividend of $0.13.

Institutional Investors Weigh In On First Trust Nasdaq Pharmaceuticals ETF

A number of institutional investors have recently made changes to their positions in the stock. LPL Financial LLC increased its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 9.3% during the fourth quarter. LPL Financial LLC now owns 55,876 shares of the company’s stock valued at $1,507,000 after acquiring an additional 4,776 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 17.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 16,403 shares of the company’s stock valued at $442,000 after purchasing an additional 2,384 shares during the period. Summit Investment Advisors Inc. boosted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 13.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,173 shares of the company’s stock valued at $382,000 after purchasing an additional 1,633 shares during the period. Finally, Vivaldi Capital Management LP boosted its stake in shares of First Trust Nasdaq Pharmaceuticals ETF by 15.6% in the fourth quarter. Vivaldi Capital Management LP now owns 8,677 shares of the company’s stock valued at $243,000 after purchasing an additional 1,171 shares during the period.

About First Trust Nasdaq Pharmaceuticals ETF

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.